Dr. Scott Rocklage Continues His Research
Dr. Scott Rocklage co-founded 5AM Ventures Management in 2002 and serves as their managing partner. He helped launch this private firm after noticing the need for next generation life science-based investments and so forth. They invest in companies that specifically develop active research instruments, drug administration technologies, therapeutics, biopharmaceuticals and also the involvement of researching and discovering breakthroughs relating to the subject. So far, 5AM Ventures has invested in more than fifty-four different next-gen life science-based companies, these also include startups.
Over the years he has seen a significant increase in new alternative methods to uniquely treat cancer by targeting certain mutations or genotypes. Dr. Rocklage is excited for the new developments and hopes it will eventually save lives in the future. He studies new existing areas of life science while working at his firm, which is still in its early stages due to the nature of their business.
Dr. Scott Rocklage has served as the chairman of the board at Cidara Therapeutics and Semprus BioSciences Corp from the years of 2013 to 2014. Prior to becoming a founder partner at 5AM Ventures Management, he served as the president of Cubist Pharmaceuticals, Inc. from the years throughout 1994 to 2001. Dr. Scott Rocklage has had over 30 years of experience in the healthcare management sector and actively serves as chairman of the board of directors for Expansion Therapeutics and is also their founding investor.
Dr. Scott M. Rocklage was born on July 28, 1954 in Palm Beach Gardens, Florida. He attended the University of California, Berkeley and graduated with a B.S. degree in Chemistry. He would later graduate with a Ph.D. in Chemistry at the Massachusetts Institute of Technology. As an M.I.T. student, Dr. Rocklage would conduct his researches in the same laboratory of Nobel Prize winner and American chemist, Richard Royce Schrock.
Scott M. Rocklage Ph.D. is a businessman, scientist, entrepreneur and investor. He has accumulated decades of experience in a variety of fields ranging from pharmaceuticals to business. Rocklage first joined the 5AM Ventures team in 2003 as a Venture Partner. After a year of success, he decided to rejoin as a Managing Partner, offering him more responsibility and control.
The 5AM Venture team has seen many accomplishments under the guidance and efforts of Scott Rocklage. His years of experience and expertise have been manifested through the growth of the company itself. Read more: Scott Racklage | Bloomberg
Before investing time in business and pharmaceuticals, Scott Rocklage attended the University of California, Berkley where he received his Bachelors of Science in Chemistry. This degree eventually led to the attendance of the prestigious Massachusetts Institute of Technology where Scott completed his Ph.D. in Chemistry.
It was this extensive education that propelled Rocklage into the world of pharmaceuticals. In addition to his educational accomplishments, Rocklage also has been awarded with approval of the Food and Drug Administration for several drugs he has helped to develop.
Scott Rocklage has also written over 100 peer-reviewed publications through which he addresses several subjects within chemistry and pharmaceuticals. He has also been the co-inventor or inventor regarding 30 United States patents. At MIT, Rocklage conducted research in the laboratory of the Nobel Prize in Chemistry in 2005 winner Richard R. Schrock.
Beyond 5AM ventures, Rocklage has over three decades of experience in healthcare management. Rocklage’s extensive experience has seen his election on the board of several well-known companies. He currently serves as the Chairman for Kinestral, Rennovia and Cidara.
He serves on the board for Pulmatrix and Epirus currently. In the past, Rocklage served as President and CEO of Nycomed Salutar as well as CEO and Chairman for Cubist Pharmaceuticals. Under Rocklage’s guidance and leadership, three U.S. New Drug Applications were approved by the FDA. The three drugs include Cubicin®, Omniscan™ and Teslascan®.
Due to his considerable contributions to pharmaceutical development and research, many companies seek Rocklage for top positions on their boards. His guidance and expertise have led to the ongoing success of many companies.